https://www.selleckchem.com/pr....oducts/LY2228820.htm
Accumulating evidence indicates that TAMs are essential regulators of chemoresistance. We have recently found that elevated levels of YKL-39 expression are indicative of the efficiency of the metastatic process in patients who undergo neoadjuvant chemotherapy. We suggest YKL-39 as a new target for anti-angiogenic therapy that can be combined with neoadjuvant chemotherapy to reduce chemoresistance and inhibit metastasis in breast cancer patients. Copyright © 2020 Kzhyshkowska, Larionova and Liu.[This corrects the article DOI 10.3389/fi
Aimer
Commentaire
Partagez
